157 related articles for article (PubMed ID: 37370730)
21. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
Nemati Shafaee M; Goutsouliak K; Lin H; Bevers TB; Gutierrez-Barrera A; Bondy M; Arun B
Breast Cancer Res Treat; 2022 Nov; 196(1):143-152. PubMed ID: 36006499
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
23. Multicenter cross-sectional screening of the
Wei H; Wang M; Ou J; Jiang W; Tian F; Sheng Y; Li H; Xu H; Zhang R; Guan A; Wang C; Jiang H; Ren Y; He J; Liu J; Huang W; Liao N; Cai X; Ming J; Ling R; Xu Y; Hu C; Zhang J; Guo B; Ouyang L; Shuai P; Liu Z; Zhong L; Jing R; Zeng Z; Zhang M; Zhang T; Xuan Z; Tan X; Liang J; Pan Q; Chen L; Zhang F; Fan L; Zhang Y; Yang X; Li J; Chen C; Jiang J
Oncol Lett; 2018 Jun; 15(6):9420-9428. PubMed ID: 29805665
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.
Rogozińska-Szczepka J; Utracka-Hutka B; Grzybowska E; Maka B; Nowicka E; Smok-Ragankiewicz A; Zientek H; Steffen J; Wojciechowska-Łacka A
Ann Oncol; 2004 Sep; 15(9):1373-6. PubMed ID: 15319244
[TBL] [Abstract][Full Text] [Related]
26. Mutational Analysis of
Stella S; Vitale SR; Martorana F; Massimino M; Pavone G; Lanzafame K; Bianca S; Barone C; Gorgone C; Fichera M; Manzella L
Cancer Manag Res; 2022; 14():1341-1352. PubMed ID: 35411189
[TBL] [Abstract][Full Text] [Related]
27. BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.
Toss A; Molinaro E; Venturelli M; Domati F; Marcheselli L; Piana S; Barbieri E; Grandi G; Piombino C; Marchi I; Tenedini E; Tagliafico E; Tazzioli G; Cortesi L
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429297
[TBL] [Abstract][Full Text] [Related]
28. Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among
Faermann R; Friedman E; Kaidar-Person O; Weidenfeld J; Brodsky M; Shalmon A; Halshtok Neiman O; Gotlieb M; Yagil Y; Samoocha D; Madorsky Feldman D; Sklair-Levy M
Breast J; 2022; 2022():4317693. PubMed ID: 36349178
[TBL] [Abstract][Full Text] [Related]
29. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in
Gaba F; Blyuss O; Tan A; Munblit D; Oxley S; Khan K; Legood R; Manchanda R
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900415
[TBL] [Abstract][Full Text] [Related]
30. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
[TBL] [Abstract][Full Text] [Related]
31. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis.
Tinterri C; Di Maria Grimaldi S; Sagona A; Barbieri E; Darwish S; Bottini A; Canavese G; Gentile D
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627205
[TBL] [Abstract][Full Text] [Related]
33. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
[TBL] [Abstract][Full Text] [Related]
34. "High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis".
Shraga S; Grinshpun A; Zick A; Kadouri L; Cohen Y; Maimon O; Adler-Levy Y; Zeltzer G; Granit A; Maly B; Carmon E; Meiner V; Sella T; Hamburger T; Peretz T
Front Oncol; 2021; 11():683656. PubMed ID: 34540661
[TBL] [Abstract][Full Text] [Related]
35. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Ha SM; Chae EY; Cha JH; Kim HH; Shin HJ; Choi WJ
AJR Am J Roentgenol; 2017 Oct; 209(4):920-928. PubMed ID: 28796549
[TBL] [Abstract][Full Text] [Related]
36. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
37. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
38. Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
Cortesi L; Canossi B; Battista R; Pecchi A; Drago A; Dal Molin C; Toss A; De Matteis E; Marchi I; Torricelli P; Cascinu S
Int J Cancer; 2019 Mar; 144(5):1001-1009. PubMed ID: 30098212
[TBL] [Abstract][Full Text] [Related]
39. Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
Chavarri-Guerra Y; Villarreal-Garza C; Ferrigno AS; Mohar A; Aguilar D; Alvarez-Gomez RM; Gallardo-Alvarado L; Del Toro-Valero A; Quintero-Beulo G; Gutierrez-Delgado F; Rodriguez-Olivares JL; Ochoa-Chavez MF; Gutierrez-Seymour G; Castillo D; Herzog J; Weitzel JN
Salud Publica Mex; 2022 Feb; 64(1):41-48. PubMed ID: 35438911
[TBL] [Abstract][Full Text] [Related]
40. The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.
You C; Xiao Q; Zhu X; Sun Y; Di G; Liu G; Hou Y; Chen C; Wu J; Shao Z; Gu Y; Hu Z
Gland Surg; 2021 Jan; 10(1):262-272. PubMed ID: 33633982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
